RAG2: A Protein Involved in Many Cellular Processes (G5897)

Target Name: RAG2

NCBI ID: G5897

RAG2

RAG2: A Protein Involved in Many Cellular Processes

RAG2 (RAG2 variant 1) is a protein that is expressed in many tissues throughout the body, including the immune system, heart, and kidneys. It is a member of the transforming growth factor-beta (TGF-β) superfamily and is involved in the regulation of cell growth, differentiation, and survival. RAG2 has been identified as a potential drug target and is the focus of ongoing research in the field of pharmacology.

The RAG2 protein is composed of 256 amino acid residues and has a molecular weight of 31 kDa. It is expressed in many tissues throughout the body, including the immune system, heart, and kidneys. RAG2 is involved in the regulation of cell growth, differentiation, and survival, and has been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of RAG2 is its role in the regulation of TGF-β signaling. TGF-β is a cytokine that plays a central role in the regulation of cell growth, differentiation, and survival, and is involved in the development and progression of many diseases, including cancer. RAG2 is a critical regulator of TGF-β signaling, and has been shown to play a role in the regulation of TGF-β activity in a variety of tissues and cells.

In addition to its role in TGF-β signaling, RAG2 is also involved in the regulation of cell adhesion and migration. RAG2 has been shown to play a role in the regulation of cell adhesion, and is involved in the development and maintenance of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues. RAG2 is also involved in the regulation of cell migration, and has been shown to play a role in the development and progression of various types of cancer.

RAG2 has also been shown to be involved in the regulation of inflammation and immune responses. RAG2 is a critical regulator of the immune response, and has been shown to play a role in the regulation of T cell development and function. RAG2 is also involved in the regulation of inflammation, and has been shown to play a role in the development and progression of various types of inflammatory diseases.

Despite its involvement in a wide range of physiological processes, RAG2 is not well understood, and much of its function and regulation remains unexplored. However, research into RAG2 is ongoing, and there is growing interest in the potential of RAG2 as a drug target.

One of the challenges in studying RAG2 is its complex and multifaceted function. RAG2 is involved in the regulation of many different processes in the body, and it is likely that many different mechanisms are involved in its regulation. Further research is needed to fully understand the functions of RAG2 and its role in the regulation of cellular processes.

In addition to its potential as a drug target, RAG2 is also of interest as a biomarker. The regulation of RAG2 by TGF-β is a well-established process, and can be used as a model for the regulation of other proteins that are involved in cellular processes. RAG2 has also been shown to be involved in the regulation of cell adhesion, and its regulation of cell adhesion may be a useful biomarker for the diagnosis and treatment of certain types of cancer.

In conclusion, RAG2 is a protein that is involved in the regulation of many different cellular processes in the body. Its role in the regulation of TGF-β signaling, cell adhesion, and immigration, as well as its involvement in the regulation of inflammation and immune responses, make it an attractive target for

Protein Name: Recombination Activating 2

Functions: Core component of the RAG complex, a multiprotein complex that mediates the DNA cleavage phase during V(D)J recombination. V(D)J recombination assembles a diverse repertoire of immunoglobulin and T-cell receptor genes in developing B and T-lymphocytes through rearrangement of different V (variable), in some cases D (diversity), and J (joining) gene segments. DNA cleavage by the RAG complex occurs in 2 steps: a first nick is introduced in the top strand immediately upstream of the heptamer, generating a 3'-hydroxyl group that can attack the phosphodiester bond on the opposite strand in a direct transesterification reaction, thereby creating 4 DNA ends: 2 hairpin coding ends and 2 blunt, 5'-phosphorylated ends. The chromatin structure plays an essential role in the V(D)J recombination reactions and the presence of histone H3 trimethylated at 'Lys-4' (H3K4me3) stimulates both the nicking and haipinning steps. The RAG complex also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. The introduction of DNA breaks by the RAG complex on one immunoglobulin allele induces ATM-dependent repositioning of the other allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. In the RAG complex, RAG2 is not the catalytic component but is required for all known catalytic activities mediated by RAG1. It probably acts as a sensor of chromatin state that recruits the RAG complex to H3K4me3 (By similarity)

The "RAG2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAG2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets